Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial

Authors

Institutions

Publication Details

Journal
Nephrology Dialysis Transplantation
Published
2025-08-13
DOI
https://doi.org/10.1093/ndt/gfaf160
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial

Amy K. Mottl, Jennifer B. Green, Sung Gyun Kim, Hiddo J.L. Heerspink et al.
Nephrology Dialysis Transplantation
Diabetes Treatment and Management
article

Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial

Amy K. Mottl, Jennifer B. Green, Sung Gyun Kim, Hiddo J.L. Heerspink, Masaomi Nangaku, Katja Rohwedder, Johannes F.E. Mann, Julio Rosenstock, Janet B. McGill, Rajiv Agarwal, Charlie Scott, Muthiah Vaduganathan, Peter R Rossing, Li Li, Na Li
article en

Abstract

No abstract available for this paper.
Nephrology Dialysis TransplantationVol. 41(1)
University of Copenhagen (DK), Brigham and Women's Hospital (US), University of North Carolina Health Care (US), University Medical Center Groningen (NL), Steno Diabetes Centers (DK), Harvard University (US), Bayer (United States) (US), Duke University (US), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Washington University in St. Louis (US), Clinical Research Institute (US), Richard L. Roudebush VA Medical Center (US), KfH Kuratorium für Dialyse und Nierentransplantation (DE), Velocity Clinical Research (United States) (US), Bayer (China) (CN), Hallym University Sacred Heart Hospital (KR), Indiana University – Purdue University Indianapolis (US), Bayer (Germany) (DE), The University of Tokyo (JP)
Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer, Sanofi, Gilead Sciences, Alnylam Pharmaceuticals, Regeneron Pharmaceuticals, Bayer HealthCare, Novo Nordisk, Astellas Pharma, Akebia Therapeutics, National Institutes of Health, Chugai Pharmaceutical, Daiichi Sankyo Europe
Openalex Percentile: Top 69%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.